Molecular replacement for cancer metabolic and mitochondrial dysfunction, fatigue and the adverse effects of cancer therapy

Cancer Genomics and Proteomics

Volumn 3, Issue 3-4, 2006, Pages 159-168

  Nicolson, Garth L ^a   Conklin, Kenneth A ^b  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Chemotherapy; Coenzyme Q10; Electron transport chain; Lipid peroxidation; Lipid replacement; Mitochondria; Oxidative stress

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; LIPID; METHOTREXATE; NTFACTOR; NUCLEOSIDE; OXALIPLATIN; PLATINUM DERIVATIVE; PROPAX; RETINOL; TAXANE DERIVATIVE; TENIPOSIDE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RESEARCH; FATIGUE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG FIBROSIS; MALAISE; MEMBRANE DAMAGE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL MEMBRANE; MUCOSA INFLAMMATION; MYOCARDIAL DISEASE; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PAIN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; QT PROLONGATION; RASH; RECTUM CANCER; REVIEW; SIDE EFFECT; SYSTOLIC TIME INTERVAL; TASTE DISORDER; THYROID CANCER; VOMITING;

EID: 33746608208     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Betteridge DJ: What is oxidative stress? Metabolism 49(suppl 1): 3-8, 2000.
2. Kehrer JP: Free radicals and mediators of tissue injury and disease. Crit Rev Toxicol 23: 21-48, 1993.
3. Halliwell B: Oxidative stress, nutrition and health. Free Rad Res 25: 57-74, 1996.
4. Cerutti PA: Prooxidant status and tumor promotion. Science 227: 375-381, 1985.
5. Dreher D and Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer 32A: 30-38, 1996.
6. Abidi S and Ali A: Role of oxygen free radicals in the pathogenesis and etiology of cancer. Cancer Lett 142: 1-9, 1999.
7. van Ginkel G and Sevanian A: Lipid peroxidation-induced membrane structural alterations. Methods Enzymol 233: 273-288, 1994.
8. Stadtman E: Introduction to serial reviews on oxidatively modified proteins in aging and disease. Free Rad Biol Med 32: 789, 2002.
9. Hsie AW, Recio I, Katz DS, Lee CQ, Wagner M and Schenley RL: Evidence for reactive oxygen species inducing mutations in mammalian cells. Proc Natl Acad Sci USA 83: 9616-9620, 1986.
10. Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 21: 361-370, 2000.
11. Bartsch H and Nair J: Oxidative stress and lipid peroxidation-driven DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prevention 28: 385-391, 2004.
12. Castro L and Freeman BA: Reactive oxygen species in human health and disease. Nutrition 17: 295-307, 2001.
13. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA and Finkel T: Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 93: 11848-11852, 1996.
14. Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267, 2004.
15. Barber DA and Harris SR: Oxygen free radicals and antioxidants: a review. Am Pharm 34: 26-35, 1994.
16. Sun Y: Free radicals, antioxidant enzymes and carcinogenesis. Free Rad Biol Med 8: 583-599, 1990.
17. Fridovich I: Superoxide radical and superoxide dismutases. Annu Rev Biochem 64: 97-112, 1995.
18. Seifried HE, McDonald SS, Anderson DE, Greenwald P and Milner JA: The antioxidant conundrum in cancer. Cancer Res 61: 4295-4298, 2003.
19. Jagetia GC, Rajanikant GK, Rao SK and Baliga MS: Alteration in the glutathione, glutathione peroxidase, superoxide dismutase and lipid peroxidation by ascorbic acid in the skin of mice exposed to fractionated gamma radiation. Clinica Chimica Acta 332: 111-121, 2003.
20. Schwartz JL: The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. J Nutr 126: 1221S-1227S, 1996.
21. Aeschbach R, Loliger J, Scott BC, Murica A, Butler J, Halliwell B and Oi A: Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chem Toxicol 32: 31-36, 1994.
22. Tanaka T: Cancer chemoprevention by natural products. Oncol Rep 1: 1139-1155, 1994.
23. Prasad KN, Cole WC, Kumar B and Prasad KC: Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Amer Coll Nutrition 20: 450S-453S, 2001.
24. Toyokuni S, Okamoto K, Yodio J and Hiai H: Persistent oxidative stress in cancer. FEBS Lett 358: 1-3, 1995.
25. Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267, 2004.
26. Brown NS and Bicknell R: Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3: 323-327, 2001.
27. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S and Husain SA: Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 59: 163-170, 2000.
28. Conklin KA: Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37: 1-18, 2000.
29. Tas F, Hansel H, Belce A, Ilvan S, Argon A, Camlica H and Topuz E: Oxidative stress in breast cancer. Med Oncol 22: 11-15, 2005.
30. Asal NR, Risser DR, Kadamani S, Geyer JR, Lee ET and Cheng N: Risk factors in renal cell carcinoma. I. Methodology, demographics, tobacco beverage use and obesity. Cancer Detect Prev 11: 359-377, 1988.
31. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK and Yu MC: Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma. Cancer Causes Control 13: 287-293, 2002.
32. Sikka SC: Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention - a mechanistic approach. Curr Med Chem 10: 2679-2692, 2003.
33. Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, Ozgok Y and Dimovski A: Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostate hyperplasia. Clin Biochem 39: 176-179, 2006.
34. Otamiri T and Sjodahl R: Increased lipid peroxidation in malignant tissues of patients with colorectal cancer. Cancer 64: 422-425, 1989.
35. Oxdemirler G, Pabucçoglu H, Bulut T, Bugra D, Uysal M and Toker G: Increased lipoperoxide levels and antioxidant system in colorectal cancer. J Cancer Res Clin Oncol 124: 555-559, 1989.
36. Manoharan, Kolanjiappan K, Suresh K and Panjamurthy K: Lipid peroxidation and antioxidants status in patients with oral squamous cell carcinoma. Ind J Med Res 122: 529-534, 2005.
37. Seril DN, Liao J, Yang GY and Yang CS: Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 34: 353-362, 2003.
38. Batcioglu K, Mehmet N, Ozturk IC, Yilmaz M, Aydogdu N, Erguvan R, Uyumlu B, Gene M and Karagozler AA: Lipid peroxidation and antioxidant status in stomach cancer. Cancer Investig 24: 18-21, 2006.
39. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M and Olinksi R: Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett 341: 59-64, 1992.
40. Demple B and Harrison L: Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 63: 915-948, 1994.
41. Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Intgr Cancer Ther 3: 294-300, 2004.
42. Esterbauer H, Schaur RJ and Zollner H: Chemistry and biochemistry of 4-hydroxynonenals, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991.
43. Dianzani MU: Lipid peroxidation and cancer. Crit Rev Oncol Hematol 15: 125-147, 1993.
44. Hauptlorenz S, Esterbauer H, Moll W, Pumpel R, Schauenstein E and Puschendorf B: Effects of the lipidperoxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochem Pharmacol 34: 3803-3809, 1985.
45. Gonzalez MJ: Lipid peroxidation and tumor growth: an inverse relationship. Med Hypotheses 38: 106-110, 1992.
46. Schackelford RE, Kaufmann WK and Paules RS: Oxidative stress and cell cycle checkpoint function. Free Rad Biol Med 28: 1387-1404, 2000.
47. Balin AK, Goodman DBF, Rasmussen H and Cristofalo VJ: Oxygen-sensitive stages of the cell cycle of human diploid cells. J Cell Biol 78: 390-400, 1978.
48. Kurata S: Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. J Biol Chem 275: 23413-23416, 2000.
49. Wei Q, Frazier ML and Levin B: DNA repair: a double edge sword. J Natl Can Inst 92: 440-441, 2000.
50. Fojo T: Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Can Inst 93: 1434-1436, 2001.
51. Zhen W, Link CJ, O'Connor PM, Reed E, Parker R, Howell SB and Bohr VA: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Molec Cell Biol 12: 3689-3698, 1992.
52. Chandra J, Samali A and Orrenius S: Triggering and modulation of apoptosis by oxidative stress. Free Rad Biol Med 29: 323-333, 2000.
53. Hampton MB and Orrenius S: Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 414: 552-556, 1997.
54. Hampton MB, Fadeel B and Orrenius S: Redox regulation of the caspases during apoptosis. Ann New York Acad Sci 854: 328-335, 1998.
55. Shacter E, Williams JA, Hinson RM, Senturker S and Lee Y-J: Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 96: 307-313, 2000.
56. Lee Y-J and Shacter E: Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 274: 19792-19798, 1999.
57. Buckingham R, Fitt J and Sitzia J: Patients' experience of chemotherapy: side-effects of carboplatin in the treatment of carcinoma of the ovary. Eur J Cancer Care 6: 59-71, 1997.
58. Loke YK, Price D, Derry S and Aronson JK: Case reports of suspected adverse drug reactions - systematic literature survey of follow-up. Br Med J 232: 335-339, 2006.
59. Vogelzang N, Breitbart W, Cella D et al: Patient caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 34(Suppl 2): 4-12, 1997.
60. Romanelli A, Bozzone A, Magrone G et al: Cancer-related fatigue: evaluation and treatment. Rays 29: 453-455, 2004.
61. Bender CM, Ergyn FS, Rosenzweig MQ et al: Symptom clusters in breast cancer across three phases of the disease. Cancer Nurs 28: 219-225, 2005.
62. Ahlberg K, Ekman T and Gaston-Johansson F: Fatigue, psychological distress, coping resources, and functional status during radiotherapy for uterine cancer. Oncol Nurs Forum 32: 633-640, 2005.
63. Shafqat A, Einhorn LH, Hanna N et al: Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 16: 1545-1550, 2005.
64. Liu L, Marler MR, Parker BA, Jones V, Sadler GR, Dimsdale J, Cohen-Zion M and Fiorentino L: The relationship between fatigue and light exposure during chemotherapy. Support Care Cancer 13: 1010-1017, 2005.
65. Von Roenn JH and Paice JA: Control of common, non-pain cancer symptoms. Semin Oncol 32: 200-210, 2005.
66. Nicolson GL: Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathol Oncol Res 11: 139-144, 2005.
67. Kroenke K, Wood DR, Mangelsdorff AD et al: Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA 260: 929-934, 1988.
68. Morrison JD: Fatigue as a presenting complaint in family practice. J Family Pract 10: 795-801, 1980.
69. McDonald E, David AS, Pelosi AJ and Mann AH: Chronic fatigue in primary care attendees. Psychol Med 23: 987-998, 1993.
70. Piper BF, Linsey AM and Dodd MJ: Fatigue mechanism in cancer. Oncol Nursing Forum 14: 17-23, 1987.
71. Piper BF, Dribble SL, Dodd MJ et al: The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nursing Forum 25: 667-684, 1998.
72. Nicolson GL: Lipid replacement as an adjunct to therapy for chronic fatigue, anti-aging and restoration of mitochondrial function. J Am Nutraceut Assoc 6(3): 22-28, 2003.
73. Huang H and Manton KG: The role of oxidative damage in mitochondria during aging: a review. Front Biosci 9: 1100-1117, 2004.
74. Richter C, Par JW and Ames B: Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Nat Acad Sci USA 85: 6465-6467, 1998.
75. Wei YH and Lee HC: Oxidative stress, mitochondrial DNA mutation and impairment of antioxidant enzymes in aging. Exp Biol Med 227: 671-682, 2002.
76. Harman D: Aging: a theory based on free radical and radiation chemistry. J Gerontol 2: 298-300, 1956.
77. Halliwell B: Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716, 2001.
78. Chen D, Cao G, Hastings T et al: Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J Neurochem 81: 1273-1284, 2002.
79. Xu D and Finkel T: A role for mitochondria as potential regulators of cellular life span. Biochem Biophys Res Commun 294: 245-248, 2002.
80. Logan AC and Wong C: Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 6: 450-459, 2001.
81. Manuel y Keenoy B, Moorkens G, Vertommen J et al: Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 68: 2037-2049, 2001.
82. Richards RS, Roberts TK, McGregor NR et al: Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 5: 35-41, 2000.
83. Felle S, Mecocci P, Fano G et al: Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biol Med 29: 1252-1259, 2000.
84. Pall ML: Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses 54: 115-125, 2000.
85. Castro L, Rodriguez M and Radi R: Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J Biol Chem 269: 29409-29415, 1994.
86. Radi R, Rodriguez M, Castro L and Teilen R: Inhibition of mitochondrial electronic transport by peroxynitrite. Arch Biochem Biophys 308: 89-95, 1994.
87. Kanno T, Sato EE, Muranaka S, Fujita H, Fujiwara T, Utsumi T, Inoue M and Utsumi K: Oxidative stress underlies the mechanism for Ca(2+)-induced permeability transition of mitochondria. Free Radical Res 38: 27-35, 2004.
88. Nicolson GL, Poste G and Ji T: Dynamic aspects of cell membrane organization. Cell Surface Rev 3: 1-73, 1977.
89. Subczynski WK and Wisniewska A: Physical properties of lipid bilayer membranes: relevance to membrane biological functions. Acta Biochim Pol 47: 613-625, 2000.
90. Nicolson GL and Ellithrope R: Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J Chronic Fatigue Syndr 13(1): 57-68, 2005.
91. Agadjanyan M, Vasilevko V, Ghochikyan A et al: Nutritional supplement (NTFactor®) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr 11(3): 23-26, 2003.
92. Hajri T and Abumrad NA: Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 22: 383-415, 2002.
93. Hamilton JA: Fatty acid transport: difficult or easy? J Lipid Res 39: 467-481, 1998.
94. Fellmann P, Herve P, Pomorski T, Muller P et al: Transmembrane movement of diether phospholipids in human erythrocytes and human fibroblasts. Biochem 39: 4994-5003, 2000.
95. Conner SD and Schmid SL: Regulated portals of entry into the cell. Nature 422: 37-44, 2003.
96. Mansbach CM and Dowell R: Effect of increasing lipid loads on the ability of the endoplasmic reticulum to transport lipid to the Golgi. J Lipid Res 41: 605-612, 2000.
97. Ames BM: Micronutrients prevent cancer and delay aging. Toxicol Lett 102: 1035-1038, 1998.
98. Seidman M, Khan MJ, Tang WX and Quirk WS: Influence of lecithin on mitochondrial DNA and age-related hearing loss. Otolaryngol Head Neck Surg 127: 138-144, 2002.
99. Ellithorpe RR, Settineri R and Nicolson GL: Reduction of fatigue by use of a dietary supplement containing glycophospholipids. J Am Nutraceut Assoc 6(1): 23-28, 2003.
100. Colodny L, Lynch K, Farber C, Papish S et al: Results of a study to evaluate the use of Propax® to reduce adverse effects of chemotherapy. J Am Nutraceut Assoc 2(1): 17-25, 2000.
101. 10 for prevention of anthracycline-induced cardiotoxicity. Intgr Cancer Ther 4: 110-130, 2005.
102. 10. Cancer Treat Rep 65: 79-91, 1981.
103. 10 in rabbits. In: Biomedical and Clinical Aspects of Coenzyme Q, Volume II. Yamamura Y, Folkers K, Ito Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 189-204, 1980.
104. 10. Toxicol Lett 12: 75-82, 1982.
105. Ghione M and Bertazzoli C: CoQ and anthracycline associated cardiomyopathy. In: Biomedical and Clinical Aspects of Coenzyme Q. Folkers K, Yamamura Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 183-199, 1977.
106. 10. In: Biomedical and Clinical Aspects of Coenzyme Q, Volume II. Yamamura Y, Folkers K, Ito Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 213-224, 1980.
107. Van Vleet JF, Greenwood L, Ferrans VJ and Rebar AH: Effect of selenium-vitamin E on Adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res 39: 997-1010, 1978.
108. Breed JGS, Zimmerman ANE, Dormans JAMA and Pinedo HM: Failure of the antioxidant vitamin E to protect against Adriamycin-induced cardiotoxicity in the rabbit. Cancer Res 40: 2033-2038, 1980.
109. Milei J, Boveris A, Llesuy S et al: Amelioration of Adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J 111: 95-102, 1986.
110. Van Vleet JF and Ferrans VJ: Evaluation of vitamin E and selenium protection against chronic Adriamycin toxicity in rabbits. Cancer Treat Rep 64: 315-317, 1980.
111. Van Vleet JF, Ferrans VJ and Weirich WE: Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 99: 13-24, 1980.
112. 10 reduction of Adriamycin cardiotoxicity. In: Biomedical and Clinical Aspects of Coenzyme Q, Volume IV. Folkers K, Yamamura Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 231-241, 1984.
113. 10. Cancer Treat Rep 62: 887-891, 1978.
114. 10 to Adriamycin treated cancer patients. In: Biomedical and Clinical Aspects of Coenzyme Q. Folkers K, Yamamura Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 267-278, 1977.
115. 10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molec Aspects Med 15: S207-S212, 1994.
116. 10. In: Biomedical and Clinical Aspects of Coenzyme Q, Volume II. Yamamura Y, Folkers K, Ito Y (eds.). Amsterdam, Elsevier/North- Holland Biomedical Press, pp. 447-454, 1980.
117. 10. In: Biomedical and Clinical Aspects of Coenzyme Q, Volume III. Folkers K, Yamamura Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 399-412, 1981.
118. 10 on ECG changes induced by doxorubicin (Adriamycin). In: Biomedical and Clinical Aspects of Coenzyme Q, Volume V. Folkers K, Yamamura Y (eds.). Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 247-256, 1986.
119. 10 administration on cardial toxicity in FAC therapy. Gan To Kagaku Ryoho 9: 116-121, 1982.
120. 10 against the side-effects of anthracycline antineoplastic agents. Gan To Kagaku Ryoho 11: 1420-1427, 1984.
121. Yamamura Y: A survey of the therapeutic uses of coenzyme Q. In: Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone Coenzyme Q. Lenaz G (ed.). Chichester, John Wiley & Sons, pp. 479-505, 1985.